According to the Zhitong Finance App, Federal Pharmaceuticals (03933) announced that the Group's net profit for the six months ended June 30, 2026 is expected to be approximately RMB 340 million (same in units), while net profit for the six months ended June 30, 2025 is approximately RMB 1,893 million.

The decrease in net profit was affected by declining market prices and demand adjustments in the intermediate products and APIs segment. In addition, license fee revenue from Novo Nordisk A/S (Novo Nordisk) in the first half of 2026 was about 101 million yuan, while license fee revenue from Novo Nordisk A/S in the first half of 2025 was about 1,433 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.